Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de la Influencia de la Insuflación Intraperitoneal de CO2 por Laparoscopia en la Evolución a Corto Plazo de Recién Nacidos Prematuros con Enterocolitis Ulcerosa Necrotizante (NECO2)

4 de noviembre de 2026 actualizado por: Assistance Publique - Hôpitaux de Paris

Estudio de la Influencia de la Insuflación Intraperitoneal de Dióxido de Carbono (CO2) por Laparoscopia en la Evolución a Corto Plazo de Recién Nacidos Prematuros con Enterocolitis Ulcerosa Necrotizante

Ulcerative-necrotizing enterocolitis (ECUN) is an infectious and inflammatory disease of the digestive tract, which can lead to intestinal necrosis or perforation.

This severe pathology of the newborn , often premature, requires urgent medical and surgical treatment in 25 to 50% of cases. The morbidity is high, both digestive and neurological. ECUN can lead to complications at short-term (death, intestinal stenosis) and at long-term (neuro-cognitive disorders). The challenge of preserving the neurological development is a major issue. It involves control of inflammation. This inflammation causes neurological lesions and is responsible for a disorder of the long-term neurocognitive development.

At Robert-Debré and Trousseau, the management of newborns with ECUN is focused on the control of this inflammation. A laparoscopy is performed first. The carbon dioxide (CO2) insufflated into the abdomen during a laparoscopy is thought to have an anti-inflammatory effect according to several experimental and clinical studies. A preliminary retrospective study at Robert-Debré showed a decrease in postoperative inflammation (decrease in C reactive protein at Day2 and Day 7 post-op) as well as a decrease in morbimortality (decrease in the rate of stoma and reoperation) in children who had a laparoscopic first operation compared to those who had a laparotomy alone. However, in many hospitals, laparotomy alone is currently the only surgical option.

This preliminary study may demonstrate that laparoscopy decreases early morbidity and mortality in children with ECUN through reduced inflammation, as reflected by postoperative C reactive protein.

Descripción general del estudio

Descripción detallada

NECO2 is a pilot trial, evaluating the intermediate effectiveness to short/medium term of laparoscopy on the inflammatory reaction of premature newborns with complicated ECUN, requiring surgical treatment.

This is a multicenter randomized controlled trial in single blind, in two parallel arms, in ratio 1:1, of superiority.

This trial compares laparoscopy plus laparotomy versus laparotomy alone.

Children will be randomized into 2 groups:

  • Laparoscopy + laparotomy group
  • Laparotomy group

The main objective is to evaluate the inflammatory response Day 2 postoperative in preterm infants with ECUN who have undergone surgery.

The main criterion is the evolution of the blood C reactive protein level between Day 0 and Day 2 postoperatively.

The secondary objectives are:To evaluate in premature babies with ECUN who have had a surgical intervention (laparoscopy + laparotomy or laparotomy alone):

A.The postoperative biological inflammatory response at Day 7 B.Post-operative biological inflammatory response from Day 0 to Day 7 C.Post-operative mortality D.Post-operative bowel morbidity E.Post-operative re-intervention rate F.Length of hospital stay G.Post-operative neurological morbidity, medium term (corrected term 41 SA)

  • To evaluate the tolerance of laparoscopy :

H.Intraoperative cardiorespiratory I.Loco-regional lesions linked to the insertion of the trocar

Secondary endpoints:

A. C reactive protein blood level at Day 7 B. Blood levels of Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha at Day 1, Day 2, Day 4, Day 7 C. Postoperative death from any cause D. Stoma rate, duration of parenteral nutrition, duration of hemodynamic support, duration of invasive ventilation (High frequency oscillatory ventilation/Synchronized Intermittent Mandatory Ventilation), Post-ECUN intestinal stenosis rate E. Re-intervention (laparotomy) and cause (post-ECUN stenosis, stoma closure) F. Length of hospital stay until return home G. Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at the corrected term of 41 weeks of amenorrhea, H. Oxygen saturation (SaO2), hypercapnia (pCO2) blood pressure (BP), cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively I. Intraoperative clinical monitoring: exploration of adjacent organs. Post-operative clinical monitoring: digestive signs monitoring of wounds until discharge.

Group 1: laparotomy only Group 2: laparotomy and laparoscopy

Tipo de estudio

Intervencionista

Inscripción (Estimado)

54

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Arnaud BONNARD, Pr
  • Número de teléfono: +33 1 40 03 23 59
  • Correo electrónico: arnaud.bonnard@aphp.fr

Ubicaciones de estudio

      • Paris, Francia, 75012
        • Reclutamiento
        • Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale
        • Contacto:
      • Paris, Francia
        • Reclutamiento
        • Hôpital Robert Debré Service de Chirurgie Pédiatrique
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Premature newborn (term of birth: <37 weeks of amenorrhea)
  • Diagnosis of ECUN by the surgeon (distension abdominal +/- rectal bleeding +/- green gastric residue, increased biological inflammatory syndrome, + pneumatosis on abdominal radiography)
  • Hospitalized and complicated ECUN: presenting either a pneumoperitoneum on abdominal X-ray or a absence of clinical and biological improvement after 48 hours of maximum well-conducted medical treatment (IV antibiotic therapy and digestive rest).
  • Hospitalized in the 2 participating centers
  • Of which the 2 holders of parental authority have been informed and have signed the consent form
  • Having social security coverage (social security or CMU)

Exclusion Criteria:

  • Instability contraindicating movement to the operating room or contraindicating CO2 insufflation
  • Diagnosis of isolated perforation of the small intestine (radiography:

pneumoperitoneum without pneumatosis)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Laparotomy

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Experimental: Laparotomy and laparoscopy

Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
C reactive protein blood level
Periodo de tiempo: between Day 0 and Day 2 post surgery

C reactive protein blood level

between Day 0 and Day 2 post surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative biological inflammatory reaction
Periodo de tiempo: Day 7 post surgery

C reactive protein blood level

Day 7 post surgery
Specific post-operative biological inflammatory reaction
Periodo de tiempo: Day1, day 2, day 4 and day 7 post surgery

Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha blood level

Day1, day 2, day 4 and day 7 post surgery
Postoperative mortality
Periodo de tiempo: up to 3 months

Death due to any postoperative cause

up to 3 months
Postoperative intestinal morbidity: stoma rate
Periodo de tiempo: up to 3 months

Stoma rate

up to 3 months
Postoperative intestinal morbidity: Duration of parenteral nutrition
Periodo de tiempo: up to 3 months

Duration of parenteral nutrition

up to 3 months
Postoperative intestinal morbidity: Duration of hemodynamic support
Periodo de tiempo: up to 3 months

Duration of hemodynamic support

up to 3 months
Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)
Periodo de tiempo: up to 3 months

Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)

up to 3 months
Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN
Periodo de tiempo: up to 3 months

Rate of intestinal stenosis post-ECUN

up to 3 months
Postoperative reoperation rate
Periodo de tiempo: up to 3 months

Reoperation (laparotomy) and cause (post ECUN stenosis, stoma closure)

up to 3 months
Length of hospitalization
Periodo de tiempo: up to 3 months

Duration of hospitalization until return home

up to 3 months
Medium-term postoperative neurological morbidity
Periodo de tiempo: up to 3 months

Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at term corrected for 41 weeks of amenorrhea

up to 3 months
Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Periodo de tiempo: During Surgery

Oxygen saturation (SaO2)

During Surgery
Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Periodo de tiempo: During Surgery

hypercapnia (pCO2)

During Surgery
Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Periodo de tiempo: During Surgery

blood pressure (systolic and diastolic)

During Surgery
Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Periodo de tiempo: During Surgery

cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively

During Surgery
Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy)
Periodo de tiempo: up to 3 months

Presence of loco-regional lesions related to the insertion of the trocar

up to 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de febrero de 2024

Finalización primaria (Actual)

22 de junio de 2025

Finalización del estudio (Estimado)

22 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

24 de abril de 2023

Primero enviado que cumplió con los criterios de control de calidad

26 de mayo de 2023

Publicado por primera vez (Actual)

31 de mayo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir